

Original Research Article

Sildenafil Determination by Using UPLC in Different Italian Viagra Tablets

Aims: The introduction of generics drugs has brought the need for more control of their quality and purity. In Italy from June 23, 2013 the Pfizer has no longer the patent for the Viagra's production and other industries produce equivalent products containing Sildenafil citrate..

Study design: Thus, in this work, the chemical profiles of both Viagra Italian Pfizer and 3 Italian commercial Sildenafil citrate tables (generic pharmaceutical manufacturers) for male erectile dysfunction were obtained by using Ultra-Performance Liquid Chromatography (UPLC).

Methodology: UPLC methodology was successfully used for the assay of Sildenafil citrate in different products in Italy which are under the cover of alternative systems of medicine.

Results: The results show that. i) the chromatographic profiles obtained from Italian Viagra tablets are identical and not present other active pharmaceutical ingredients; ii) the commercial samples have a quantity of Sildenafil citrate comparable with the corresponding labelled amounts.

Conclusion: The UPLC method can be used for determination of Sildenafil citrate tables marketed by generic pharmaceutical manufacturers in Italy.

Keywords: Chemical profile, UPLC, Pharmaceutical preparations, Sildenafil, Stress testing, Viagra.

1. INTRODUCTION

Male erectile dysfunction (ED), known as impotence, is a type of male sexual dysfunction [1]. It is characterized by the inability to develop and maintain the erected penis during sexual performance [1,2]. It is generally accepted to adversely affect the quality of life and some indication it is frequently associated with some disorders such as depression, anxiety which can have several psychological consequences tied to relationship difficulties and masculine self-image generally [3]. The causes may be different. In general it is divided two types: generally psychological, physical and organic, related to the drugs itself or to the lifestyle and diseases [4].

Medical therapy for this condition was unsatisfactory for invasiveness or inefficacy before the introduction of Sildenafil citrate known as Viagra [5]. Sildenafil citrate was patented in 1996 and launched in May 1998 as first oral medical drug approved by Food and Drug Administration (FDA) to treat this type of male dysfunction. It's a white to off-white crystalline powder with a molecular weight of 666.7 Dalton. Molecular formula is C₂₂H₃N₆O₄S, chemically, designed as 1-[(3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H pyrazolo[4,3-d]pyrimidin-5yl)-4-ethoxyphenyl)sulfonyl]-4-methylpiperazine citrate. The parasympathetic nerves are stimulated when man arouses sexually, leading to penile erection as result of release of nitric oxide (NO) which active enzyme guanylate cyclase responsible for

converting guanosine triphosphate (GTP) to 3',5' cyclic guanosine monophosphate (cGMP). This last is a potent vasodilator vital erection of penis. Sildenafil citrate inhibits the enzyme PDE-5A (phosphodiesterase-5A) that idrolize cGMP. Thus, it increases level of cGMP by preventing it from breaking down. Consequently smooth muscle relaxation leads to vasodilation and increased inflow of blood into the spongy tissue of the penis causing an erection by fascinating the signaling actions of nitric oxide (NO) in penile smooth muscle [6].

For many years after being originally developed by British scientists, Sildenafil citrate was a substance marketed exclusively by Pfizer as a pharmaceutical company Pfizer [7]. Pfizer, until 23 June 2013 had the patent of substance Sildenafil citrate to sell medicines containing the active substance. After the patent was expired and other companies have had the opportunity to sell products containing Sildenafil citrate with the same results on patients. Thus, there are few information on the quality and purity (chemical profile) of these products.

In this context we develop our research that for the first time compares the Sildenafil citrate marketed by generic pharmaceutical manufacturers in Italy trough using the reproducibile and sensitive method of UPLC system.

2. MATERIAL AND METHODS

2.1 Chemicals, drugs and buffers

The standard of Sildenafil citrate is purchased from Sigma-Aldrich (Milan, Italy). The UPLC grade methanol, triethanolamine, phosphoric acid were provided by Carlo Erba (Milan, Italy). the 50 mg tablets Viagra produced by Pfizer (leader, Pfizer Italia Srl, Latina, Italy) was used as reference. Three Italian Sildenafil citrate generic drugs [Sildenafil DOC generics (50 mg; DOC generic Srl, Milan, Italy), Silderafil EG (50 mg; EG SpA, Milan, Italy) and Sildenafil Ranbaxy (50 mg; Ranbaxy Italia SpA, Milan, Italy)] which are sold under the cover of alternate system of medicines in Italy were purchased from local pharmacy of Caserta. The purified water prepared by Milli-Q system was used for the preparation of buffer and other aqueous solutions.

The following eluents were used: eluent A, 70 mL triethanolamine in a purified water sufficient to make 1000 mL. The pH 4.0 was adjusted by use of 85% phosphoric acid; eluent B, methanol. Eluents was filtered through 0.22 µm filter.

2.2 Instrumentation

The LC system used for the analyses consisted of an Acquity UPLC with PDA detector (Waters, Vimodrone, Milan, Italy), and a separated module with an BEH C-18 column (50 x 2.1 mm, 1.7 µm particle size; Waters), set at 45°C operating temperature. Empower software (Waters) was used for data treatment. The RP-HPLC method of Mahmood et al, 2010 [8] was been adapted for UPLC by using Waters software tool. The analysis was carried out using an isocratic elution as previously mentioned containing 92% eluent A and 8% eluent B at flow rate of 0.8 mL/min. Eluted Sildenafil citrate was monitored at 290 nm. The injection volume was 3.0 µL. In the case of necessity, buffer A was used for sample dilution. Separation of all drugs was achieved with a total run time of 5 minutes. The retention time of Sildenafil citrate is normally 1.78 min. Solutions of standard: The solution was prepared with external standard Sildenafil citrate by diluting with mobile phase. The samples at concentration of 4.6, 4.1, 3.6, 3.1 and 2.6 µg/mL were also prepared by diluting stock solution of external standard sildenafil citrate in mobile phase for constructing standard

80 curve, in quintuplicate [9]. We also mixed these samples and ultrasonicated them for 30
81 minutes. At the end, we filtered the solution through 0.22µm.

82

83 **2.3 Degradation of Sildenafil citrate drugs**

84 Degradation of Sildenafil citrate samples (leader and the generic drugs) with
85 chemical reagent was carried out as already described [10]. Typically, 30 mg of Sildenafil
86 citrate were treated with chemical treatment in 2 mL and then the mixture neutralized (final
87 volume 50 mL). The following chemical treatments were employed: (i) 30% H₂O₂; (ii) 37%
88 HCl; (iii) 10 M NaOH. After the chemical treatments all samples were stored for 15 minutes
89 at the room temperature and analyzed by UPLC. Temperature stability of medicines
90 dissolved in water was also tested storing Sildenafil citrate samples for 12 hour at 80°C in
91 dark. Then we analyses the samples using UPLC analyses. As reference (standard
92 preparation), 30 mg of Sildenafil citrate (leader and the generic drug samples) were
93 dissolved in neutralized without treatment (final volume 50 mL).

94

95 **3. RESULTS AND DISCUSSION**

96


97 **3.1 Linearity of UPLC method achieved**

98 The retention time of Sildenafil citrate was 1.78 min in the new adapted method
99 respected to the elution time of 7.8 min as it is previously reported by Mahmood using RP-
100 HPLC [8]. Moreover, there was no peak when placebo mobile phase was run. The
101 calibration curve for Sildenafil was found to be linear over the range of 2.6- 4.6 µg/mL (Fig.
102 1A).

103

104

105



106

107

108 **Fig. 1: A**, standard calibration curve and linearity plots for Sildenafil citrate (Sigma-Aldrich)
 109 quantitation. In the inset, the equation and R² values of calibration. **B**, UPLC elution
 110 profiles of Italian Viagra tables (50 mg tablets from Pfizer, DOC generic, EG,
 111 Ranbaxy Italia) on an Acquity UPLC with PDA detector from reverse-phase
 112 chromatography using a C-18 column. Experimental conditions are described in the
 113 text.

114

115 3.2 Analyses of Sildenafil citrate samples in pure form using UPLC


116 A set of 4 Viagra samples (Viagra 50 mg tablets from Pfizer, DOC generic, EG SpA,
 117 Ranbaxy Italia SpA) were analyzed by UPLC. Fig. 2B showed the typical chromatogram
 118 profiles of Sildenafil citrate samples (leader and the generic drugs). In all samples, Sildenafil
 119 was eluted with the same elution time at the presence of the high purity content, without any
 120 interference peak. In all tables the recovered percentage of Sildenafil citrate was about
 121 99.80% with Relative Standard Deviation (R.D.S.) of 0.5%. The obtained results for the four
 122 samples were comparable with to the corresponding labelled amounts of the five replicate
 123 injections of standard preparation (data not shown).

124

125 3.3 Degradation of Sildenafil citrate samples to verify specificity

126 The specificity was demonstrated by the induced degradation of Sildenafil citrate
 127 samples we treated them with either 37% HCl and storing them at 25°C for 15 min, or 10 M
 128 NaOH, and storing at 25°C for 15 min, 30% H₂O₂ and storing the sample at 25°C for 15 min
 129 or heating dissolved medicines in water and testing the samples stored at 80° for 12 hour. In
 130 the case of 37% M HCl (Fig. 2A) and 10 M NaOH (Fig. 2B), respectively, the recovery of
 131 Sildenafil in all samples was 101.7 and 99.3 % with a total degradation of 0.2 and 0.4 %.

132



133

134

135 **Fig. 2:** Elution profiles of Italian market formulation of Viagra samples (50 mg tablets from
 136 Pfizer, DOC generic, EG SpA, Ranbaxy Italia SpA) after chemical treatment under
 137 acid (A) or basic (B) conditions.

138

139 Vice versa Sildenafil citrate samples were found to be susceptible to H₂O₂ (Fig. 3A). We
 140 detected the impurity B (5-[2-ethoxy-5-[(4-methyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl]-1-
 141 methyl-3-propyl-1,6-dihydro-7Hpyrazolo[4,3-d]pyrimidin-7-one) in all Viagra samples as
 142 previously reported [11]. However, the decomposition showed a Sildenafil recovery of 65.0
 143 % and also the presence of impurity B of about 35%. Considering the heating treatment the
 144 chromatographic profiles show the presence of unknown peak which represents degradation

of 0.2% (Fig. 3B). Therefore the characterization of this degradation was not carried out for the minimal amount.




Fig. 3: Elution profiles of Italian market formulation of Viagra samples (50 mg tablets from Pfizer, DOC generic, EG SpA, Ranbaxy Italia SpA) after chemical treatment with hydrogen peroxide (A) or heating (B) conditions.

4. CONCLUSION

In the proposed study the collected data shows that all the Italian formulations of Viagra tablets analyzed by the UPLC did not present another unknown pharmaceutical ingredients and the commercial samples have the same quantity of Sildenafil citrate as labelled. Furthermore, the analysis carried out after chemical-physical treatment confirm that each formulation was very resistant to acid and basic treatments and only in the presence of hydrogen peroxide there is a partially degradation of the Sildenafil citrate.

165 REFERENCES

166
167 1 Montague D K, Jarow J P, Broderick G A, Dmochowski R R, Heaton J P, Lue T F,
168 Milbank A J, Nehra A, Sharlip I D. Chapter 1: The management of erectile dysfunction:
169 an AUA update. J Urol 2005;174:230-239.
170 2 Rosenberg M T. Diagnosis and management of erectile dysfunction in the primary
171 care setting. Int J Clin Pract 2007;61:1198-1208.
172 3 Moore T M, Strauss J L, Herman S, Donatucci C F. Erectile dysfunction in early,
173 middle, and late adulthood: symptom patterns and psychosocial correlates. J Sex
174 Marital Ther 2003;29:381-399.
175 4 AAVV. Erectile Dysfunction Causes. Erectile Dysfunction. Healthcommunities 1998.
176 5 Boolell M, Allen M J, Ballard S A, Gepi-Attee S, Muirhead G J, Naylor A M, Osterloh I
177 H, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase
178 inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
179 6 Webb D J, Freestone S, Allen M J, Muirhead G J. Sildenafil citrate and blood-
180 pressure-lowering drugs: results of drug interaction studies with an organic nitrate and
181 a calcium antagonist. Am J Cardiol 1999;83:21C-28C.
182 7 Kling J. From hypertension to angina to Viagra. Modern Drug Discovery 1998;1:31-38.
183 8 Mahmood K T, Khan B. A validated HPLC method for the measurement of Sildenafil
184 Citrate in different formulations. Pakistan Journal of Science 2010;62:192-197.
185 9 Giaretta N, Di Giuseppe AMA, Lippert M, Parente A, Di Maro A. Myoglobin as marker
186 in meat adulteration: a UPLC method for determining the presence of pork meat in
187 raw beef burger. Food Chem 2013;141:1814-1820
188 10 Mahmoudian M. Sildenafil determination in various matrices: A review. Iranian Journal
189 of Pharmacology & Therapeutics 2005;4:72-75.
190 11 Pharmacopoeia E. Sildenafil citrate. European Pharmacopoeia 7.6 2012;5053-5054.

191
192
193
194
195
196
197
198
199
200
201
202
203

APPENDIX
NO